These results imply that neovascularisation does not always accompany MO, although both are affected dominantly by the same cytokine (VEGF), and that anti-VEGF treatment targeting MO control does not satisfactorily suppress neovascularisation, regardless of the underlying retinal diseases. This evidence concerns the gene VEGFA and Abnormal retinal morphology.